Twice-a-Year Injection for HIV Prevention Shows Remarkable 96% Risk Reduction
Remarkable Results from Lenacapavir Trial
A recent Phase 3 clinical trial revealed that a twice-a-year injection of lenacapavir provides a dramatic reduction in the risk of HIV infection, outperforming existing daily PrEP pills. According to Gilead Sciences, 99.9% of participants did not acquire HIV during the trial, showcasing an impressive 96% risk reduction.
Significance of the PURPOSE 2 Trial
The PURPOSE 2 trial involved diverse participant demographics across 88 sites in various countries, highlighting the potential for lenacapavir to reach marginalized populations. This breakthrough is expected to enhance HIV prevention efforts globally.
Implications for HIV Prevention Efforts
- Lenacapavir could increase adherence rates compared to daily pills.
- Potential authorization in high-incidence areas by the end of the year.
- Significant impact on the pursuit of an AIDS-free generation.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.